Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,869 | -31,658 | -16,810 | -17,793 | -9,763 |
| Depreciation Amortization | -158 | 647 | 645 | 581 | 375 |
| Accounts receivable | 1,283 | -2,891 | -50,227 | -162 | -56 |
| Accounts payable and accrued liabilities | -916 | 1,413 | 5,107 | 238 | 105 |
| Other Working Capital | 3,186 | 34,113 | -11,870 | 1,801 | 864 |
| Other Operating Activity | 2,139 | 2,419 | 41,463 | -2,013 | 847 |
| Operating Cash Flow | $-8,335 | $4,043 | $-31,692 | $-17,348 | $-7,628 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -500 | -587 | -322 | -347 | -323 |
| Purchase Of Investment | N/A | -70,877 | -46,548 | -38,611 | -17,241 |
| Sale Of Investment | 8,177 | 80,810 | 60,355 | 45,860 | 20,935 |
| Investing Cash Flow | $7,677 | $9,346 | $13,485 | $6,902 | $3,371 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 117 | 611 | 509 | 410 | 306 |
| Common Stock Issued | N/A | 15 | 15 | 15 | N/A |
| Other Financing Activity | -214 | -343 | -225 | -119 | -36 |
| Financing Cash Flow | $-97 | $283 | $299 | $306 | $270 |
| Exchange Rate Effect | 1,026 | -4,208 | -8,629 | -4,862 | -1,159 |
| Beginning Cash Position | 100,333 | 90,869 | 90,869 | 90,869 | 90,869 |
| End Cash Position | 100,604 | 100,333 | 64,332 | 75,867 | 85,723 |
| Net Cash Flow | $271 | $9,464 | $-26,537 | $-15,002 | $-5,146 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,335 | 4,043 | -31,692 | -17,348 | -7,628 |
| Capital Expenditure | -500 | -587 | -322 | -347 | -323 |
| Free Cash Flow | -8,835 | 3,456 | -32,014 | -17,695 | -7,951 |